hrcak mascot   Srce   HID

Izvorni znanstveni članak

Intravitreal Bevacizumab for the Management of Age-Related Macular Degeneration

Damir Kovačević
Tea Čaljkušić-Mance
Tamara Mišljenović
Maša Mikuličić
Zvjezdana Alpeza-Dunato

Puni tekst: engleski, pdf (49 KB) str. 5-7 preuzimanja: 314* citiraj
APA 6th Edition
Kovačević, D., Čaljkušić-Mance, T., Mišljenović, T., Mikuličić, M. i Alpeza-Dunato, Z. (2008). Intravitreal Bevacizumab for the Management of Age-Related Macular Degeneration. Collegium antropologicum, 32 - Supplement 2 (2), 5-7. Preuzeto s https://hrcak.srce.hr/34450
MLA 8th Edition
Kovačević, Damir, et al. "Intravitreal Bevacizumab for the Management of Age-Related Macular Degeneration." Collegium antropologicum, vol. 32 - Supplement 2, br. 2, 2008, str. 5-7. https://hrcak.srce.hr/34450. Citirano 17.06.2021.
Chicago 17th Edition
Kovačević, Damir, Tea Čaljkušić-Mance, Tamara Mišljenović, Maša Mikuličić i Zvjezdana Alpeza-Dunato. "Intravitreal Bevacizumab for the Management of Age-Related Macular Degeneration." Collegium antropologicum 32 - Supplement 2, br. 2 (2008): 5-7. https://hrcak.srce.hr/34450
Harvard
Kovačević, D., et al. (2008). 'Intravitreal Bevacizumab for the Management of Age-Related Macular Degeneration', Collegium antropologicum, 32 - Supplement 2(2), str. 5-7. Preuzeto s: https://hrcak.srce.hr/34450 (Datum pristupa: 17.06.2021.)
Vancouver
Kovačević D, Čaljkušić-Mance T, Mišljenović T, Mikuličić M, Alpeza-Dunato Z. Intravitreal Bevacizumab for the Management of Age-Related Macular Degeneration. Collegium antropologicum [Internet]. 2008 [pristupljeno 17.06.2021.];32 - Supplement 2(2):5-7. Dostupno na: https://hrcak.srce.hr/34450
IEEE
D. Kovačević, T. Čaljkušić-Mance, T. Mišljenović, M. Mikuličić i Z. Alpeza-Dunato, "Intravitreal Bevacizumab for the Management of Age-Related Macular Degeneration", Collegium antropologicum, vol.32 - Supplement 2, br. 2, str. 5-7, 2008. [Online]. Dostupno na: https://hrcak.srce.hr/34450. [Citirano: 17.06.2021.]

Sažetak
The aim of this study is to report short-term effect of the treatment of »wet« ARMD (age-related macular degeneration)
with intravitreal bevacizumab (Avastin). Prospective study included 36 patients (36 eyes) with »wet« form of ARMD. All
patients were over 60 year old (22 female, 14 male). Changes of macula included minimally classic CNV (choroidal
neovascularisation) (24), occult subfoveal CNV (10) and first stage of cicatrial CNV (2). Bevacizumab 1.25 mg was administered
intravitreally through pars plana using a 27-gauge needle. Patients had no previous eye treatment. Ophthalmic
exam before and after the treatment included: Snellen VA (visual acuity) and examination including measurement of
IOP (intraocular pressure), FA (fluorescein angiography) and interview with patients. After 4–6 weeks 28 (78%) patients
had significant improvement of VA. Median VA improved from 0.083 to 0.200 (p<0.01). Eight patients (22%) had no significant
improvement in VA but three of them reported to see more light. FA showed complete resolution of macular
edema in 6 patients (17%), partially resolved in 23 patients (64%) and no change in 7 patients (19%). No systemic side-effect
was found. Short-term results suggest that intravitreally administered bevacizumab is well tolerated treatment for
ARMD with very high number of patients showing improvement in VA.

Ključne riječi
bevacizumab; choroidal neovascularization; age-related macular degeneration

Hrčak ID: 34450

URI
https://hrcak.srce.hr/34450

Posjeta: 491 *